Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 5/20 | 0.61 |
| ▸ | MMP12 | P39900 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13932240 | 1.00 | NR3C2 (0.61) | NR3C2MMP12PARP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4269356 | 0.88 | MMP12 (0.64) | NR3C2MMP12PARP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13932049 | 0.88 | MMP12 (0.64) | NR3C2MMP12PARP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13932108 | 0.86 | NR3C2 (0.55) | NR3C2MMP12PARP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4261242 | 0.86 | NR3C2 (0.55) | NR3C2MMP12PARP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4266691 | 0.85 | NR3C2 (0.63) | NR3C2MMP12PARP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13932042 | 0.85 | NR3C2 (0.63) | NR3C2MMP12PARP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4258190 | 0.85 | NR3C2 (0.62) | NR3C2MMP12PARP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13932129 | 0.85 | NR3C2 (0.62) | NR3C2MMP12PARP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4259274 | 0.84 | NR3C2 (0.57) | NR3C2MMP12ALDH1A1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054417-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | IRM LLC (BM) | 2009-02-26 | — | — | US | claimed |
| JP-2008508314-A | — | — | 2008-03-21 | — | — | JP | claimed |
| EP-1778242-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | IRM LLC (BM) | 2007-05-02 | — | — | EP | claimed |
| WO-2006015259-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | IRM LLC (BM) | 2006-02-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054417-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | NR5A1, ESRRA, NR3C1 | NR3C2 7/4885MMP12 2999/4885PARP1 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.